91 results on '"Jihao Zhou"'
Search Results
2. A chest CT-based nomogram for predicting survival in acute myeloid leukemia
- Author
-
Xiaoping Yi, Huien Zhan, Jun Lyu, Juan Du, Min Dai, Min Zhao, Yu Zhang, Cheng Zhou, Xin Xu, Yi Fan, Lin Li, Baoxia Dong, Xinya Jiang, Zeyu Xiao, Jihao Zhou, Minyi Zhao, Jian Zhang, Yan Fu, Tingting Chen, Yang Xu, Jie Tian, Qifa Liu, and Hui Zeng
- Subjects
Chest computed tomography ,CT-derived features ,Acute myeloid leukemia ,Nomogram ,Prognosis ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The identification of survival predictors is crucial for early intervention to improve outcome in acute myeloid leukemia (AML). This study aim to identify chest computed tomography (CT)-derived features to predict prognosis for acute myeloid leukemia (AML). Methods 952 patients with pathologically-confirmed AML were retrospectively enrolled between 2010 and 2020. CT-derived features (including body composition and subcutaneous fat features), were obtained from the initial chest CT images and were used to build models to predict the prognosis. A CT-derived MSF nomogram was constructed using multivariate Cox regression incorporating CT-based features. The performance of the prediction models was assessed with discrimination, calibration, decision curves and improvements. Results Three CT-derived features, including myosarcopenia, spleen_CTV, and SF_CTV (MSF) were identified as the independent predictors for prognosis in AML (P
- Published
- 2024
- Full Text
- View/download PDF
3. Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatin
- Author
-
Jichao Sun, Dinglan Wu, Liuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Chengchao Xu, Zhijie Li, and Jigang Wang
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Chimeric antigen receptor natural killer (CAR-NK) therapy holds great promise for treating hematologic tumors, but its efficacy in solid tumors is limited owing to the lack of suitable targets and poor infiltration of engineered NK cells. Here, we explore whether immunogenic cell death (ICD) marker ERp57 translocated from endoplasmic reticulum to cell surface after drug treatment could be used as a target for CAR-NK therapy.Methods To target ERp57, a VHH phage display library was used for screening ERp57-targeted nanobodies (Nbs). A candidate Nb with high binding affinity to both human and mouse ERp57 was used for constructing CAR-NK cells. Various in vitro and in vivo studies were performed to assess the antitumor efficacy of the constructed CAR-NK cells.Results We demonstrate that the translocation of ERp57 can not only be induced by low-dose oxaliplatin (OXP) treatment but also is spontaneously expressed on the surface of various types of tumor cell lines. Our results show that G6-CAR-NK92 cells can effectively kill various tumor cell lines in vitro on which ERp57 is induced or intrinsically expressed, and also exhibit potent antitumor effects in cancer cell-derived xenograft and patient-derived xenograft mouse models. Additionally, the antitumor activity of G6-CAR-NK92 cells is synergistically enhanced by the low-dose ICD-inducible drug OXP.Conclusion Collectively, our findings suggest that ERp57 can be leveraged as a new tumor antigen for CAR-NK targeting, and the resultant CAR-NK cells have the potential to be applied as a broad-spectrum immune cell therapy for various cancers by combining with ICD inducer drugs.
- Published
- 2024
- Full Text
- View/download PDF
4. Correction: A chest CT-based nomogram for predicting survival in acute myeloid leukemia
- Author
-
Xiaoping Yi, Huien Zhan, Jun Lyu, Juan Du, Min Dai, Min Zhao, Yu Zhang, Cheng Zhou, Xin Xu, Yi Fan, Lin Li, Baoxia Dong, Xinya Jiang, Zeyu Xiao, Jihao Zhou, Minyi Zhao, Jian Zhang, Yan Fu, Tingting Chen, Yang Xu, Jie Tian, Qifa Liu, and Hui Zeng
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2024
- Full Text
- View/download PDF
5. Efficacy and toxicity of SEAM (semustine, etoposide, cytarabine, and melphalan) conditioning regimen followed by autologous stem cell transplantation in lymphoma
- Author
-
Lihong Zhang, Haifei Yang, Chongsheng Qian, Jihao Zhou, Qian Zhu, Yibin Jiang, Shuo Liu, Xiaochen Chen, Ting Xu, Changju Qu, Caixia Li, Zhengming Jin, Jianhong Chu, Xinyou Zhang, Depei Wu, and Haiwen Huang
- Subjects
semustine ,carmustine ,SEAM ,lymphoma ,autologous stem cell transplantation ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Objectives The aim of this retrospective study was to evaluate the safety and efficacy of SEAM regimen followed by auto-SCT in lymphoma.Patients and methods We retrospectively reviewed the records of patients with lymphoma who underwent auto-SCT with SEAM conditioning regimen from January 2010 to June 2018 at our centre. In total, 97 patients were analysed.Results The median time to neutrophil engraftment and platelet engraftment was 9.5 days (range, 7–15 days) and 12 days (range, 7–25 days), respectively. Grade 3–4 nausea/vomiting, mucositis and diarrhoea were observed in 21.6%, 36.1%, and 11.3% of patients, respectively. Treatment-related mortality at 100 days occurred in 2 patients (2.1%). After a median follow-up time of 53.9 months, the 3-year incidence of disease relapse or progression was 34%. The estimated progression-free survival and overall survival at 3 years were 62% and 75%, respectively. Compared with previous studies using BEAM as the conditioning regimen, this study shows that the SEAM regimen has a comparable efficacy and safety profile.Conclusions The SEAM regimen is feasible and might be an ideal alternative to BEAM regimen for lymphoma auto-SCT.
- Published
- 2022
- Full Text
- View/download PDF
6. PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
- Author
-
Jihao Zhou, Min Zuo, Lifeng Li, Fang Li, Peng Ke, Yangying Zhou, Yaping Xu, Xuan Gao, Yanfang Guan, Xuefeng Xia, Xin Yi, Xinyou Zhang, and Yuhua Huang
- Subjects
central nervous system ,diffuse large B-cell lymphoma ,molecular classification ,PIM1 ,CD79B ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Primary diffuse large B cell lymphoma of the central nervous system (CNS DLBCL) is a rare malignancy with a distinct genetic profile. The clinicopathological significance of the mutation patterns remains unknown. Forty cases of primary CNS DLBCL were subjected to targeted exome sequencing covering 413 genes, including MYD88, CD79B and PIM1. Mutational analysis recognized two groups. The CDP (including CD79B and/or PIM1mutations) group was identified in 27 cases (67.5%), and the non-CDP (without CD79B and PIM1 mutations) group was identified in 13 cases 32.5%). The CDP group tended to occur in older patients (median age 57.0 vs. 48.4 years, p=0.015). Patients in the CDP group had a significantly longer 2-year overall survival (OS) (76% and 40%, p=0.0372) than those in the non-CDP group. Multivariate analysis revealed that age less than 60 years, no MYC and BCL2 double expression, and CDP group were three independent risk factors indicating favorable OS. PyClone analysis revealed the subcloning heterogeneity between the groups. In addition, transcriptional sequencing was successfully performed in 8 cases. A total of 131 genes were significantly differentially expressed between these two groups. The major categories of biological processes that were significantly altered between these two groups related to intracellular metabolism mechanisms. We developed a new molecular classification to divide CNS DLBCL into CDP and non-CDP groups based on CD79B and PIM1 mutational status. Patients with PIM1 and/or CD79B mutations had favorable long-term survival after high-dose methotrexate-based polychemotherapy.
- Published
- 2022
- Full Text
- View/download PDF
7. Facile Preparation of b-Fe2O3/BiOCl0.875Br0.125 Composites for Enhanced Visible-light Photocatalytic Degradation of Organics from Water
- Author
-
Jihao Zhou, Zhiwei Zhao, Ping Xiao, Jie Liu, Zhaoxia Ding, Yuting Han , Jie Shi
- Subjects
Environmental effects of industries and plants ,TD194-195 ,Science (General) ,Q1-390 - Abstract
Visible light-driven photocatalytic oxidation technology has shown great potential for effective removal of organic pollutants from water and mitigation of energy crises at the same time. The highly effective and economic b-Fe2O3/BiOCl0.875Br0.125 photocatalyst was prepared by a facile hybrid compositing method with b-Fe2O3 and BiOCl0.875Br0.125 to overcome relatively high material cost and limited catalytic efficiency. Characterization techniques, such as XRD, SEM and XPS were used to study the purity and crystallization characteristics of the as-prepared photocatalyst. Furthermore, taking rhodamine b (RhB) as a simulated organic pollutant, the photocatalytic property of b-Fe2O3/BiOCl0.875Br0.125 with different Bi content was further evaluated by static catalytic degradation test under visible-light. The results indicated that the photocatalytic efficiency of the novel composites increases with the improvement of Bi content. Additionally, in comparison to equal mass of pure phase BiOCl0.875Br0.125, when the Bi content reached to 30%, a comparable and even better photocatalysis performance was achieved by the as-prepared b-Fe2O3/BiOCl0.875Br0.125. The hybrid b-Fe2O3/BiOCl0.875Br0.125 has a potential cost advantage in practical water treatment, and provide an attractive method for fabricating efficient visiblelight- driven photocatalysts.
- Published
- 2020
- Full Text
- View/download PDF
8. Enhanced adsorption of As(III) on chemically modified activated carbon fibers
- Author
-
Jie Shi, Zhiwei Zhao, Jihao Zhou, Tianyi Sun, and Zhijie Liang
- Subjects
Activated carbon fiber (ACF) ,As(III) ,Adsorption ,Modification ,Water supply for domestic and industrial purposes ,TD201-500 - Abstract
Abstract In this study, potentials of Fe- and HNO3-modified activated carbon fiber (ACF) for the adsorption of As(III) from aqueous solutions were evaluated. The adsorbent was characterized by Brunauer–Emmett–Teller (BET), scanning electron microscopy and X-ray diffraction spectra. It was found that both the modified ACF and unmodified ACF had large specific surface areas. Compared with the unmodified ACF, the crystallinity of the Fe- and HNO3-modified ACF showed a trend of decrease. The final equilibrium was achieved within approximate 60 min, and the removal of As(III) was significantly influenced by the initial pH. Isotherm simulations revealed that the ACF exhibited effective adsorption capacity for As(III) in aqueous solution. The adsorption isothermal data fitted the Langmuir isotherm model better than the Freundlich isotherm model for the unmodified ACF and HNO3-modified ACF, but the Freundlich isotherm model was more suitable for the Fe-modified ACF. According to the Langmuir models, the maximum adsorption capacity of As(III) was 2.06, 2.98 and 8.65 mg/g for ACF-0, ACF-1 and ACF-2, respectively. The results demonstrated that the adsorption capacity was enhanced significantly by Fe and HNO3 modification, and the Fe-modified ACF showed a higher potential for the adsorption of As(III) ion from aqueous solution than the unmodified ACF and HNO3-modified ACF.
- Published
- 2019
- Full Text
- View/download PDF
9. Seamless phase IIa/IIb adaptive design with the same primary endpoint for proof of concept and dose finding
- Author
-
Jiacheng Yuan, Daniel Radecki, Denise Bugarin, Till Geib, Jihao Zhou, and Jeen Liu
- Subjects
Medicine (General) ,R5-920 - Abstract
This paper considers combining a proof of concept (POC) study and a dose finding (DF) study where the POC and the DF share the same primary endpoint. An example based on real study conditions shows that compared to a conventional design the proposed adaptive design tests more active doses, with a smaller sample size and a shorter overall duration leading to a budget saving of 30% in study operations. Keywords: Adaptive design, Dose finding, Proof of concept, Seamless design, Budget saving
- Published
- 2018
- Full Text
- View/download PDF
10. Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.
- Author
-
Yushi Yao, Jihao Zhou, Lixin Wang, Xiaoning Gao, Qiaoyang Ning, Mengmeng Jiang, Jia Wang, Lili Wang, and Li Yu
- Subjects
Medicine ,Science - Abstract
As one of the best known cancer testis antigens, PRAME is overexpressed exclusively in germ line tissues such as the testis as well as in a variety of solid and hematological malignant cells including acute myeloid leukemia. Therefore, PRAME has been recognized as a promising target for both active and adoptive anti-leukemia immunotherapy. However, in most patients with PRAME-expressing acute myeloid leukemia, PRAME antigen-specific CD8(+) CTL response are either undetectable or too weak to exert immune surveillance presumably due to the inadequate PRAME antigen expression and PRAME-specific antigen presentation by leukemia cells. In this study, we observed remarkably increased PRAME mRNA expression in human acute myeloid leukemia cell lines and primary acute myeloid leukemia cells after treatment with a novel subtype-selective histone deacetylase inhibitor chidamide in vitro. PRAME expression was further enhanced in acute myeloid leukemia cell lines after combined treatment with chidamide and DNA demethylating agent decitabine. Pre-treatment of an HLA-A0201(+) acute myeloid leukemia cell line THP-1 with chidamide and/or decitabine increased sensitivity to purified CTLs that recognize PRAME(100-108) or PRAME(300-309) peptide presented by HLA-A0201. Chidamide-induced epigenetic upregulation of CD86 also contributed to increased cytotoxicity of PRAME antigen-specific CTLs. Our data thus provide a new line of evidence that epigenetic upregulation of cancer testis antigens by a subtype-selective HDAC inhibitor or in combination with hypomethylating agent increases CTL cytotoxicity and may represent a new opportunity in future design of treatment strategy targeting specifically PRAME-expressing acute myeloid leukemia.
- Published
- 2013
- Full Text
- View/download PDF
11. LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials.
- Author
-
Cox, Sue Ellen, Kaufman-Janette, Joely, Cohen, Joel L., Gold, Michael, Joseph, John, Nestor, Mark S., Rzany, Berthold, Taylor, Susan, Jihao Zhou, Cecerle, Michael, Pueraro, Elena, Irvine, Ryan, and Dayan, Steven
- Published
- 2024
- Full Text
- View/download PDF
12. Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody for the Treatment of Generalised Pustular Psoriasis: Results from the Phase 2 GALLOP Trial
- Author
-
Richard B Warren, Adam Reich, Andrzej Kaszuba, Waldemar Placek, Christopher E M Griffiths, Jihao Zhou, Bruce Randazzo, Paul Lizzul, and Johann E Gudjonsson
- Subjects
Dermatology - Abstract
Background Generalised pustular psoriasis (GPP) is a systemic inflammatory disease that can be severe, debilitating, and life-threatening. Uncontrolled activation of interleukin-36 (IL-36) pro-inflammatory activity may underlie the pathogenesis of GPP. Currently, GPP-specific treatment options are limited. Objectives To evaluate the efficacy and safety of the anti-IL-36 receptor antibody imsidolimab in subjects with GPP. Methods In an open-label, single-arm, multiple-dose study, subjects with GPP were treated with imsidolimab to assess clinical efficacy, tolerability, and safety. Subjects received an intravenous (IV) imsidolimab 750 mg dose on Day 1, followed by 3 doses of subcutaneous (SC) imsidolimab 100 mg administered on Days 29, 57, and 85. The primary efficacy endpoint was the proportion of subjects that achieved a clinical response at Week 4 and Week 16 following treatment with imsidolimab as measured by the Clinical Global Impression (CGI) scale. Results A total of 8 patients were enrolled and 6 subjects completed the study. Responses were observed as early as Day 3, most rapidly for pustulation relative to other manifestations of GPP, with continued and consistent improvement across multiple efficacy assessments at Day 8, Day 29, and through Day 113. Most treatment-emergent adverse events (TEAEs) were mild to moderate in severity. No subject discontinued the study due to a non-serious TEAE. Two subjects experienced serious adverse events (SAEs) and no deaths were reported. Conclusions Imsidolimab demonstrated a rapid and sustained resolution of symptoms and pustular eruptions in subjects with GPP. It was generally well-tolerated, associated with acceptable safety, and is advancing to Phase 3 trials. These data support targeting of IL-36 signalling with a specific antibody, imsidolimab, as a therapeutic option for this severely debilitating condition. The study was registered under EudraCT Number 2017-004021-33 and NCT 03619902.
- Published
- 2023
13. TAFRO syndrome: A disease that known is half cured
- Author
-
Tingting Chen, Chun Feng, Xinyou Zhang, and Jihao Zhou
- Subjects
Cancer Research ,Oncology ,Hematology ,General Medicine - Abstract
Thrombocytopenia, anasarca, fever, reticulin fibrosis/renal failure, and organomegaly (TAFRO) syndrome is rare in clinical practice. It is a systemic inflammatory disease caused by a cytokine storm. Its clinical manifestations include thrombocytopenia, systemic edema, fever, bone marrow fibrosis, renal insufficiency, and organ enlargement. The high mortality rate of TAFRO syndrome is due to the difficulty of acquiring biopsy samples for diagnosis and the rapid disease progression. This disease is poorly understood by clinicians. Early detection, accurate diagnosis, and timely treatment play key roles in prolonging the survival of the patients. This review summarizes the latest progress in the pathogenesis, diagnostic criteria, and treatment regimens of TAFRO syndrome, aiming to help clinicians better understand TAFRO syndrome and improve its diagnosis and treatment.
- Published
- 2022
14. The time-dependent effects of early-onset Epstein-Barr viremia on adult acute leukemia patients following allo-HSCT with ATG-containing MAC regimen
- Author
-
Depei Wu, Xiebing Bao, Xiao Ma, Feng Chen, Huiying Qiu, Zhengzheng Fu, Suning Chen, Xinyou Zhang, Xiaowen Tang, Yue Han, Qian Zhu, Song-Bai Liu, Peng Ke, and Jihao Zhou
- Subjects
Adult ,Male ,Epstein-Barr Virus Infections ,Herpesvirus 4, Human ,medicine.medical_specialty ,Time Factors ,Transplantation Conditioning ,T-Lymphocytes ,medicine.medical_treatment ,Cytomegalovirus ,Graft vs Host Disease ,Viremia ,Hematopoietic stem cell transplantation ,Gastroenterology ,MAC Regimen ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,Humans ,Medicine ,Cumulative incidence ,Antilymphocyte Serum ,Proportional Hazards Models ,Acute leukemia ,business.industry ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Hematology ,General Medicine ,Myeloablative Agonists ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,Allografts ,Prognosis ,medicine.disease ,Transplantation ,Leukemia, Myeloid, Acute ,Regimen ,Histocompatibility ,030220 oncology & carcinogenesis ,Cytomegalovirus Infections ,Female ,Virus Activation ,Unrelated Donors ,business ,Immunosuppressive Agents ,030215 immunology - Abstract
Epstein-Barr virus (EBV) viremia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The purpose of this study was to evaluate the impacts of early-onset EBV viremia in acute leukemia (AL) patients who underwent allo-HSCT with anti-thymocyte globulin (ATG)-containing myeloablative conditioning (MAC) regimen. Two hundred and ninety-six patients were included between January 2013 and December 2015. In 126 patients (42.6%) who developed early-onset EBV viremia, with a median time of 48 (range 18~99) days after allo-HSCT. The cumulative incidence of EBV viremia at 30 and 90 days after allo-HSCT were 4.1 and 39.9%, respectively. Prognostic analysis showed that the adjusted overall survival in early-EBVpos group was significantly lower than early-EBVneg group within the first 26.7 months after allo-HSCT [hazard ratio (HR), 1.63, P = 0.012], but significantly higher than those afterward (after 26.7 months: HR 0.11, P = 0.035); for the adjusted event-free survival, early-EBVpos group was significantly inferior in early-EBVpos group within the first 10.8 months after transplantation (HR: 1.55, P = 0.042), and this adverse effect was not detected any more after 10.8 months (HR: 0.58, P = 0.107). Compared with early-EBVneg group after adjusting by aGVHD and CMV viremia, HR for death from transplant-related mortality was 2.78-fold higher in patients with early-EBV viremia in piecewise constant Cox analysis (P = 0.006), and this adverse effect was not detected any more after the cut-point time (HR: 0.67, P = 0.361). No differences in terms of relapse and relapse mortality were observed between early-EBVpos and early-EBVneg group (P > 0.05). In conclusion, the impacts on transplant outcomes of early-EBV viremia were time-dependent, which may help to optimize management strategies for early-EBV viremia after allo-HSCT, especially in AL patients with ATG-containing MAC regimen.
- Published
- 2021
15. Facile Preparation of b-Fe2O3/BiOCl0.875Br0.125 Composites for Enhanced Visible-light Photocatalytic Degradation of Organics from Water
- Author
-
Shi Jie, Zhiwei Zhao, Yuting Han, Jie Liu, Zhaoxia Ding, Ping Xiao, and Jihao Zhou
- Subjects
lcsh:TD194-195 ,Materials science ,Chemical engineering ,Renewable Energy, Sustainability and the Environment ,lcsh:Environmental effects of industries and plants ,Degradation (geology) ,Visible light photocatalytic ,lcsh:Science (General) ,lcsh:Q1-390 ,General Environmental Science - Abstract
Visible light-driven photocatalytic oxidation technology has shown great potential for effective removal of organic pollutants from water and mitigation of energy crises at the same time. The highly effective and economic b-Fe2O3/BiOCl0.875Br0.125 photocatalyst was prepared by a facile hybrid compositing method with b-Fe2O3 and BiOCl0.875Br0.125 to overcome relatively high material cost and limited catalytic efficiency. Characterization techniques, such as XRD, SEM and XPS were used to study the purity and crystallization characteristics of the as-prepared photocatalyst. Furthermore, taking rhodamine b (RhB) as a simulated organic pollutant, the photocatalytic property of b-Fe2O3/BiOCl0.875Br0.125 with different Bi content was further evaluated by static catalytic degradation test under visible-light. The results indicated that the photocatalytic efficiency of the novel composites increases with the improvement of Bi content. Additionally, in comparison to equal mass of pure phase BiOCl0.875Br0.125, when the Bi content reached to 30%, a comparable and even better photocatalysis performance was achieved by the as-prepared b-Fe2O3/BiOCl0.875Br0.125. The hybrid b-Fe2O3/BiOCl0.875Br0.125 has a potential cost advantage in practical water treatment, and provide an attractive method for fabricating efficient visiblelight- driven photocatalysts.
- Published
- 2020
16. Donor CMV-specific cytotoxic T lymphocytes successfully treated drug-resistant cytomegalovirus encephalitis after allogeneic hematopoietic stem cell transplantation
- Author
-
Juan Zhuang, Xuefeng He, Jihao Zhou, Xiaoli Li, Xiebing Bao, Xinyou Zhang, Depei Wu, Peng Ke, and Xiao Ma
- Subjects
Adult ,Male ,Ganciclovir ,Foscarnet ,medicine.medical_treatment ,Congenital cytomegalovirus infection ,Cytomegalovirus ,Hematopoietic stem cell transplantation ,Drug resistance ,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma ,Antiviral Agents ,03 medical and health sciences ,0302 clinical medicine ,Drug Resistance, Viral ,Humans ,Transplantation, Homologous ,Medicine ,Cytotoxic T cell ,business.industry ,Hematopoietic Stem Cell Transplantation ,virus diseases ,Myeloid leukemia ,Hematology ,Middle Aged ,medicine.disease ,Tissue Donors ,Leukemia, Myeloid, Acute ,030220 oncology & carcinogenesis ,Cytomegalovirus Infections ,Immunology ,Encephalitis ,Female ,Complication ,business ,T-Lymphocytes, Cytotoxic ,030215 immunology ,medicine.drug - Abstract
Background: Cytomegalovirus (CMV) infection of the central nervous system (CNS) is a rare but life-threatening complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Cases presentation: Two patients with drug-resistant CMV encephalitis after allo-HSCT were successfully treated with donor CMV-specific cytotoxic T lymphocytes (CTLs). In the first case, a 27-year-old male who received haploidentical transplantation to treat T-cell acute lymphoblastic leukemia (T-ALL), developed CMV encephalitis during the time of the ganciclovir maintenance treatment. After intravenous foscarnet and donor CMV-specific CTLs, CMV-DNA of CSF became undetectable and the abnormal signs of brain magnetic resonance imaging (MRI) were limited. Another case, a 57-year-old female with acute myeloid leukemia (AML) who underwent haploidentical transplantation, also developed CMV encephalitis during the maintenance treatment of the ganciclovir. After administering donor CMV-specific CTLs intrathecally, the CMV load of the CSF decreased.Conclusions: The intravenous/intratheca administration of donor CMV-specific CTLs may be a safe and effective treatment for CMV encephalitis, especially for patients who suffered from drug-resistant CMV infection.
- Published
- 2020
17. Nano-porous Membrane Process for Brackish Groundwater Treatment: Efficiency Analysis Using Response Surface Methodology
- Author
-
Yuzheng Lv, Jihao Zhou, Zhengjun Mai and Jie Liu
- Subjects
lcsh:TD194-195 ,lcsh:Environmental effects of industries and plants ,lcsh:Science (General) ,lcsh:Q1-390 - Abstract
Excessively high concentration of inorganic salts in the groundwater is the main threat for residents to drink directly in the remote areas of northwestern China. In this paper, nano-porous membrane process was proposed to removal of diverse ions in such raw water. Through the response surface methodology (RSM), the effects of multiple factors on permeate flux and ion rejection rates were analysed, and the application scope of nanofiltration for various water resource was evaluated. It was found that the factors affecting permeate flux, chloride removal and nitrate removal (response value) followed some typical sequences, and the operating pressure was always the most influential factor. Besides, nanoporous membrane process showed predominant performance in the removal of sulphate, chloride and fluoride; the rejection rates were over 99%, 97% and 95%, respectively, and the produced water could completely satisfy the relevant national standards for drinking water. However, nitrate removal rate was seldom over 80%, and it reduced obviously with the increasing initial concentration of nitrate, thus the nitrate content of raw water should be controlled within 40 mg.L-1.
- Published
- 2019
18. Removal of Microcystis aeruginosa and control of algal organic matters by potassium ferrate(VI) pre-oxidation enhanced Fe(II) coagulation
- Author
-
Xia Peng, Zhiwei Zhao, Yuting Han, Wei Peng, Jie Liu, Ping Xiao, and Jihao Zhou
- Subjects
chemistry.chemical_classification ,biology ,Potassium ferrate ,General Chemical Engineering ,02 engineering and technology ,General Chemistry ,Comproportionation ,021001 nanoscience & nanotechnology ,biology.organism_classification ,chemistry.chemical_compound ,Adsorption ,020401 chemical engineering ,chemistry ,Environmental chemistry ,Microcystis ,Dissolved organic carbon ,Water treatment ,Organic matter ,Microcystis aeruginosa ,0204 chemical engineering ,0210 nano-technology - Abstract
The problem of cyanobacteria blooms during potable water production has generated wide concern. Ferrate(VI) serving as a pre-oxidation tactic was first applied to enhance conventional Fe(II) coagulation for Microcystis aeruginosa-laden water treatment at lab scale. Results demonstrated that ferrate(VI) pre-oxidation could successfully destabilize algae cells through destroying the protective organic layer. The residual ferrate(VI) together with post-added Fe(II) could provoke a comproportionation reaction, where large amounts of Fe hydrolyzates [Fe(OH)3] are formed. The in-situ Fe(OH)3 with abundant reactive surface is responsible for the promotion of flocs growth by facilitating the clustering and cross-linking of algal organic matters (AOM) and cyanobacteria cells, simultaneously resulting in satisfactory reductions in OD680, turbidity and UV254. Overdose of ferrate(VI) could cause severe cell destruction along with the release of intracellular organic matter (IOM), which may impair the water quality by increasing the concentration of dissolved organic carbon (DOC) and the disinfection by-products formation potential (DBPFP). Meanwhile, considering the Fe residual in settled water, the optimal ferrate(VI) dose (20 µM) and Fe(II) dose (80 µM) were proposed. Besides, the synergistic effect of both the degradation by ferrate(VI) and the adsorption by in-situ Fe(OH)3 contributed to the removal of DOC and Microcystin-LR. This study suggests that ferrate(VI) might be a potential candidate for pre-treatment to assist Fe(II) coagulation when addressing algae-laden water.
- Published
- 2019
19. 34617 Imsidolimab in the treatment of adult subjects with generalized pustular psoriasis: Design of a pivotal phase 3 clinical trial and a long-term extension study
- Author
-
Johann E. Gudjonsson, Bruce Randazzo, and Jihao Zhou
- Subjects
Dermatology - Published
- 2022
20. Combinatory strategy using nanoscale proteomics and machine learning for T cell subtyping in peripheral blood of single multiple myeloma patients
- Author
-
Henry H N Lam, Guoqiang Li, Chun Feng, Peiwu Huang, Yuan Li, Xinyou Zhang, Long Wu, Yangqiu Li, Ruijun Tian, An He, Jihao Zhou, Yun Yang, Xueting Ye, Ling Xu, and Peng Ke
- Subjects
Proteomics ,Proteome ,T cell ,T-Lymphocytes ,02 engineering and technology ,Machine learning ,computer.software_genre ,01 natural sciences ,Biochemistry ,Analytical Chemistry ,Flow cytometry ,Machine Learning ,Immune system ,medicine ,Environmental Chemistry ,Humans ,Spectroscopy ,medicine.diagnostic_test ,business.industry ,Chemistry ,010401 analytical chemistry ,021001 nanoscience & nanotechnology ,Subtyping ,0104 chemical sciences ,medicine.anatomical_structure ,Artificial intelligence ,0210 nano-technology ,business ,Multiple Myeloma ,computer ,Cytometry ,CD8 - Abstract
T cells play crucial roles in our immunity against hematological tumors by inducing sustained immune responses. Flow cytometry-based detection of a limited number of specific protein markers has been routinely applied for basic research and clinical investigation in this area. In this study, we combined flow cytometry with the simple integrated spintip-based proteomics technology (SISPROT) to characterize the proteome of primary T cell subtypes in the peripheral blood (PB) from single multiple myeloma (MM) patients. Taking advantage of the integrated high pH reversed-phase fractionation in the SISPROT device, the global proteomes of CD3+, CD4+ and CD8+ T cells were firstly profiled with a depth of >7 000 protein groups for each cell type. The sensitivity of single-shot proteomic analysis was dramatically improved by optimizing the SISPROT and data-dependent acquisition parameters for nanogram-level samples. Eight subtypes of T cells were sorted from about 4 mL PB of single MM patients, and the individual subtype-specific proteomes with coverage among 1 702 and 3 699 protein groups were obtained from as low as 70 ng and up to 500 ng of cell lysates. In addition, we developed a two-step machine learning-based subtyping strategy for proof-of-concept classifying eight T cell subtypes, independent of their cell numbers and individual differences. Our strategy demonstrates an easy-to-use proteomic analysis on immune cells with the potential to discover novel subtype-specific protein biomarkers from limited clinical samples in future large scale clinical studies.
- Published
- 2021
21. An Uncommon Case of Double-Hit Mantle Cell Lymphoma That Demonstrates a Transformation Process
- Author
-
Yaying Zhou, Lina Hu, Min Zuo, Guoqiang Li, Xinyou Zhang, and Jihao Zhou
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lymphoma, B-Cell ,Oncogene Proteins, Fusion ,Lymphoma, Mantle-Cell ,Blastoid ,CD19 ,Flow cytometry ,Proto-Oncogene Proteins c-myc ,Cytogenetics ,03 medical and health sciences ,Fatal Outcome ,0302 clinical medicine ,Cyclin D1 ,immune system diseases ,hemic and lymphatic diseases ,medicine ,Humans ,neoplasms ,In Situ Hybridization, Fluorescence ,Gene Rearrangement ,biology ,medicine.diagnostic_test ,General Medicine ,Middle Aged ,biology.organism_classification ,medicine.disease ,Immunohistochemistry ,Molecular biology ,Lymphoma ,Cell Transformation, Neoplastic ,030104 developmental biology ,030220 oncology & carcinogenesis ,Mutation ,biology.protein ,Female ,Mantle cell lymphoma ,Fluorescence in situ hybridization - Abstract
Objectives Mantle cell lymphoma (MCL) is a mature B-cell lymphoma characterized by CCND1/IGH rearrangement. We reported a case of MCL harboring both CCND1/IGH and MYC/IGH rearrangements that also presented with an aggressive clinical course. Methods Biopsy specimens were evaluated by morphological staining, immunohistochemistry, flow cytometry, conventional cytogenetics, fluorescence in situ hybridization (FISH), and next-generation sequencing (NGS). Results Morphological and immunohistochemical staining of gallbladder samples demonstrated blastoid variant MCL. However, in the bone marrow sample, FISH indicated rearrangements in CCND1/IGH and MYC/IGH. Flow cytometry identified two groups of malignant lymphocytes. We sorted these two groups of cells. NGS then revealed that both cell types carried CCND1/IGH rearrangements and TP53 mutations. Furthermore, the CD19+/CD10+ cells carried additional MYC/IGH rearrangement and NOTCH2 mutation. Conclusions The rearrangement of MYC and a mutation in NOTCH2 probably induced the transformation of MCL cells in this patient. This uncommon double-hit MCL case clearly demonstrates a transformation process.
- Published
- 2019
22. Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children
- Author
-
Peng Ke, Xiaohui Hu, Xinyou Zhang, Xiao Ma, Xiebing Bao, Yuejun Liu, Qian Zhu, Juan Zhuang, Jihao Zhou, Depei Wu, and Shengli Xue
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,medicine.medical_treatment ,Calcineurin Inhibitors ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Gastroenterology ,Disease-Free Survival ,03 medical and health sciences ,0302 clinical medicine ,Central Nervous System Diseases ,Internal medicine ,medicine ,Humans ,Cumulative incidence ,Child ,Retrospective Studies ,business.industry ,Incidence ,Incidence (epidemiology) ,Hazard ratio ,Hematopoietic Stem Cell Transplantation ,Neurotoxicity ,Infant ,Retrospective cohort study ,Hematology ,General Medicine ,Allografts ,medicine.disease ,Survival Rate ,Calcineurin ,Transplantation ,surgical procedures, operative ,Child, Preschool ,Hematologic Neoplasms ,030220 oncology & carcinogenesis ,Acute Disease ,Female ,business ,030215 immunology - Abstract
Central nervous system complications (CNSCs) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) are common and may be a significant source of morbidity and mortality. We performed a retrospective study of 153 pediatric patients who underwent allo-HSCT to determine CNSC type, incidence, and impact on survival. A total of 34 patients (22.2%) developed CNSCs. The cumulative incidence of CNSCs at 100 days and 3 years was 18.30 and 22.73%, respectively. The most common CNSC was calcineurin inhibitor (CNI)-associated neurotoxicity (50.0%). Risk factors for CNSCs were the time from diagnosis to HSCT ≥4.8 months (p = 0.032) and the development of acute graft-versus-host disease (aGVHD) grade III–IV (p = 0.002). CNSCs after allo-HSCT negatively impacted overall survival (hazard ratio [HR] 1.97, p = 0.043) and nonrelapse mortality (HR 4.84, p < 0.001). In conclusion, CNSCs after allo-HSCT are associated with poor outcomes; patients with severe aGVHD and/or late transplantation should be given more attention.
- Published
- 2019
23. Seamless phase IIa/IIb adaptive design with the same primary endpoint for proof of concept and dose finding
- Author
-
Jihao Zhou, Denise Bugarin, Daniel Radecki, Till Geib, Jeen Liu, and Jiacheng Yuan
- Subjects
Phase (waves) ,01 natural sciences ,Article ,Proof of concept ,010104 statistics & probability ,03 medical and health sciences ,Dose finding ,0302 clinical medicine ,Control theory ,Clinical endpoint ,Budget saving ,030212 general & internal medicine ,0101 mathematics ,Duration (project management) ,health care economics and organizations ,Mathematics ,Pharmacology ,lcsh:R5-920 ,Adaptive design ,General Medicine ,Sample size determination ,Seamless design ,lcsh:Medicine (General) - Abstract
This paper considers combining a proof of concept (POC) study and a dose finding (DF) study where the POC and the DF share the same primary endpoint. An example based on real study conditions shows that compared to a conventional design the proposed adaptive design tests more active doses, with a smaller sample size and a shorter overall duration leading to a budget saving of 30% in study operations. Keywords: Adaptive design, Dose finding, Proof of concept, Seamless design, Budget saving
- Published
- 2018
24. Comparison of Mitoxantrone in Combination with Intermediate-dose Cytarabine versus High-dose Cytarabine as Consolidation Therapies for Young Non-APL Acute Myeloid Leukemia Patients with Favorable and Intermediate Cytogenetics
- Author
-
Hai-qing Lin, Guoqiang Li, Jihao Zhou, Qi Shen, Sun Xiongfei, Xinyou Zhang, and Lina Hu
- Subjects
Adult ,Male ,0301 basic medicine ,Oncology ,Antimetabolites, Antineoplastic ,medicine.medical_specialty ,Biochemistry ,03 medical and health sciences ,0302 clinical medicine ,Leukemia, Promyelocytic, Acute ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Genetics ,medicine ,Humans ,Mitoxantrone ,business.industry ,Cytarabine ,Induction chemotherapy ,Myeloid leukemia ,Middle Aged ,medicine.disease ,Regimen ,Leukemia ,030104 developmental biology ,Platelet transfusion ,030220 oncology & carcinogenesis ,Absolute neutrophil count ,Female ,business ,medicine.drug - Abstract
In this study, we compared the efficacy of mitoxantrone in combination with intermediate-dose cytarabine (HAM) with that of high-dose cytarabine alone (HiDAC) as consolidation regimens in non-acute promyelocytic leukemia (APL) acute myeloid leukemia patients with favorable and intermediate cytogenetics. A total of 62 patients from Shenzhen People's Hospital were enrolled in this study. All patients enrolled received standard induction chemotherapy and achieved the first complete remission (CR1). In these patients, 24 received HiDAC and 38 received HAM as consolidation. The median relapse free survival (RFS) and overall survival (OS) were similar between these two consolidation regimens. Even in subgroup analysis according to risk stratification, the combination regimen conferred no benefit in longterm outcome in patients with favorable or intermediate cytogenetics. However, in patients receiving HAM regimen, the lowest neutrophil count was lower, neutropenic period longer, neutropenic fever rate higher, and more platelet transfusion support was required. HAM group also tended to have higher rate of sepsis than HiDAC group. According to our results, we suggest that combination treatment with mitoxantrone and intermediate-dose cytarabine has limited value as compared to HiDAC, even in young non-APL AML patients with favorable and intermediate cytogenetics.
- Published
- 2018
25. Abstract 666: PIM1 and CD79b mutation status impact outcome in primary central nervous system DLBCL after high-dose methotrexate-based chemoimmunotherapy
- Author
-
Lifeng Li, Qi Shen, Guoqiang Li, Chun Feng, Yuhua Huang, Xuefeng Xia, Peng Ke, Lina Hu, Min Zuo, Xinyou Zhang, Yanfang Guan, Yaping Xu, Xuan Gao, and Jihao Zhou
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Central nervous system ,PIM1 ,CD79B ,High dose methotrexate ,Outcome (game theory) ,medicine.anatomical_structure ,Chemoimmunotherapy ,Internal medicine ,Mutation (genetic algorithm) ,Medicine ,business - Abstract
Background: Primary central nervous system diffuse large B cell lymphoma (PCNSL) is a rare malignancy confined to the central nervous system (CNS). PCNSL has distinct molecular features,most of which harbor MYD88, CD79b and/or PIM1 mutation. Up to date,there is few study focusing on molecular classification of PCNSL. The clinicopathologic and prognostic significance of molecular classification in PCNSL remains unknown. Methods: Targeted exome sequencing covering 413 genes was conducted on 40 cases of PCNSL. The techniques of performing transcriptional sequencing on FFPE tumor tissue samples was also used following the “K.TotalRNA” protocol. All patients enrolled received high-dose methotrexate-based (HD-MTX) chemoimmunotherapy. Then, a molecular classification methodology in PCNSL patients by bioinformatic analysis was developed. Results: Targeted deep sequencing on the coding regions revealed that MYD88, CD79b and PIM1 were the three most commonly mutated genes in PCNSL patients. All cases were clustered into two molecular subgroups. Patients with PIM1 and/or CD79b mutation were clustered into the so-called CDP group; while patients without PIM1 and CD79b mutation were clustered into the so-called nonCDP group. The 2-year PFS rate was 50.0% and 29% for CDP group and nonCDP group, respectively (P=0.107). And the 2-year OS rate was 76% and 40% for CDP group and nonCDP group, respectively (P=0.037). Patients in CDP group had a prolonged long-term survival compared with those in nonCDP group. Univariate and multivariate analysis revealed that age less than 60, no Myc/Bcl2/Bcl6 double expression by immunohistochemical staining (IHC), and CDP subgroup by NGS were three independent risk factors indicating favorable OS. PyClone analysis revealed that tumor cells of nonCDP group were genetically more heterogeneous than those of CDP group. RNA sequencing analysis revealed that a total of 131 genes were significantly differentially expressed between CDP and nonCDP groups. GO enrichment analysis of these genes suggested that the major categories of biological processes that significantly altered between the two groups mainly related to drug metabolism, suggesting that tumor cells of the two groups may have different drug metabolism mechanism. Results of the PyClone analysis and RNA sequencing partially explained the different treatment sensitivity between these two groups. Conclusion: We developed a new molecular methodology to divide PCNSL into CDP and nonCDP groups, based on the mutational status of CD79b and PIM1. According to our result, PCNSL patients without PIM1 and CD79b mutation had unfavorable long-term survival after HD-MTX based chemoimmunotherapy, possibly due to their clonal heterogeneity and their different drug metabolism mechanism. Citation Format: Jihao Zhou, Min Zuo, Peng Ke, Qi Shen, Lifeng Li, Yaping Xu, Lina Hu, Guoqiang Li, Chun Feng, Xuan Gao, Yanfang Guan, Xuefeng Xia, Xinyou Zhang, Yuhua Huang. PIM1 and CD79b mutation status impact outcome in primary central nervous system DLBCL after high-dose methotrexate-based chemoimmunotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 666.
- Published
- 2021
26. Ultrasound irritation enhanced heterogeneous activation of peroxymonosulfate with Fe3O4 for degradation of azo dye
- Author
-
Jie Liu, Zhaoxia Ding, Xiao Xu, Jihao Zhou, Zhiwei Zhao, and Fang Zhendong
- Subjects
Acoustics and Ultrasonics ,Sulfate radicals ,Radical ,02 engineering and technology ,010501 environmental sciences ,medicine.disease_cause ,Photochemistry ,01 natural sciences ,Catalysis ,law.invention ,Inorganic Chemistry ,law ,medicine ,Chemical Engineering (miscellaneous) ,Environmental Chemistry ,Radiology, Nuclear Medicine and imaging ,Neutral ph ,Electron paramagnetic resonance ,0105 earth and related environmental sciences ,Chemistry ,business.industry ,Organic Chemistry ,Ultrasound ,021001 nanoscience & nanotechnology ,Irritation ,0210 nano-technology ,business ,Fe3o4 nanoparticles - Abstract
Magnetic Fe3O4 nanoparticles were synthesized and used as peroxymonosulfate (PMS) activator in the presence of ultrasound (US) irritation for azo dye degradation in this study. At pH 7.0 and temperature 298K, Fe3O4 nanoparticles were able to activate PMS under ultrasound irritation to produce sulfate radicals for acid orange 7 (AO7) removal in 30min. Higher catalysts dosage, neutral pH as well as optimum values of PMS dosage and ultrasound power favored the AO7 degradation. Fe3O4 displayed excellent stability and reusability in the US/PMS system. Both of the sulfate radicals and hydroxyl radicals were produced in the reaction and sulfate radicals were the dominant according to the scavenging tests and electron paramagnetic resonance (ESR) tests. The mechanisms of ultrasound irritation enhanced PMS activation in the presence of Fe3O4 were proposed based on the results and literatures.
- Published
- 2017
27. A Chinese family with congenital Dysfibrinogenemia carries a heterozygous missense mutation in FGA: Concerning the genetic abnormality and clinical treatment
- Author
-
Xinyou Zhang, Peng Zhu, and Jihao Zhou
- Subjects
Proband ,Pediatrics ,medicine.medical_specialty ,Anemia ,Dysfibrinogenemia ,030204 cardiovascular system & hematology ,03 medical and health sciences ,symbols.namesake ,0302 clinical medicine ,medicine ,Missense mutation ,Exome sequencing ,Sanger sequencing ,Genetics ,business.industry ,Pulmonary embolism ,General Medicine ,Hypofibrinogenemia ,medicine.disease ,Mutation (genetic algorithm) ,Mutation ,symbols ,Original Article ,Fibrinogen replacement treatment ,business ,030215 immunology - Abstract
Objectives Congenital dysfibrinogenemia is a rare hereditary disease characterized by normal antigen level but lower function level of fibrinogen. Patients with congenital dysfibrinogenemia usually present as bleeding and/or thrombotic events. In this study, we explored the genetic abnormality and clinical treatment of a Chinese family with dysfibrinogenemia. Methods This study was conducted in Jan 2015 to Jan 2016 in the Second Medical College (Shenzhen People's Hospital, Jinan University, Shenzhen, Guangdong Province, P.R. China. Coagulation function test were used to screen patients in this family. For all family members, DNA from peripheral blood was isolated. Whole-genome exon sequencing was carried out to screen possible mutations. And sanger sequencing was employed to further confirm the mutation in patients. Results The proband is a woman who had anemia and increased menstruation. Hypofibrinogenemia was found after admission. However, a pulmonary embolism occurred after the fibrinogen replacement treatment. Whole exon sequencing was conducted afterward. A candidate mutation in FGA gene (c.103C>A) was identified and validated in the woman and in two siblings. Conclusion From this case, we learned that1) point mutation of c.103C>A is the pathogenesis for congenital dysfibrinogemia in this family; 2) thromboprophylaxis should always be in consideration when fibrinogen replacement is conducted. Prospective studies are needed to determine the best fibrinogen replacement strategy in order to achieve adequate hemostasis while minimize risk of thrombosis.
- Published
- 2017
28. LBA-02 INTERNATIONAL PHASE 3, DOUBLE-BLIND, PLACEBO- AND ACTIVE (TOLTERODINE)-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF VIBEGRON IN PATIENTS WITH SYMPTOMS OF OVERACTIVE BLADDER: EMPOWUR
- Author
-
David R. Staskin, Jeffrey Frankel, Paul N. Mudd, Jihao Zhou, Rachael Jankowich, and Susann Varano
- Subjects
Agonist ,medicine.medical_specialty ,medicine.drug_class ,business.industry ,Urology ,urologic and male genital diseases ,medicine.disease ,Placebo ,female genital diseases and pregnancy complications ,Double blind ,stomatognathic diseases ,Overactive bladder ,medicine ,In patient ,Tolterodine ,business ,medicine.drug - Abstract
INTRODUCTION AND OBJECTIVES:Vibegron is a novel, once-daily, oral β3-adrenoceptor (AR) agonist in development for treatment of patients (pts) with overactive bladder (OAB). Vibegron is highly selec...
- Published
- 2019
29. BiOCl0.875Br0.125/polydopamine functionalized PVDF membrane for highly efficient visible-light-driven photocatalytic degradation of roxarsone and simultaneous arsenic immobilization
- Author
-
Junyu Fan, Jihao Zhou, Jie Liu, Xin Zhou, Zhiwei Zhao, Wei Peng, Yi Wang, Xiao Xu, and Zhaoxia Ding
- Subjects
General Chemical Engineering ,chemistry.chemical_element ,02 engineering and technology ,General Chemistry ,010402 general chemistry ,021001 nanoscience & nanotechnology ,01 natural sciences ,Industrial and Manufacturing Engineering ,0104 chemical sciences ,chemistry.chemical_compound ,Adsorption ,Membrane ,chemistry ,Chemical engineering ,Roxarsone ,Photocatalysis ,Environmental Chemistry ,Degradation (geology) ,0210 nano-technology ,Photodegradation ,Bifunctional ,Arsenic - Abstract
A bifunctional membrane modified by BiOCl0.875Br0.125 and polydopamine (PDA) was developed in the current study and employed for the photocatalytic degradation of roxarsone (ROX) under visible-light and simultaneous immobilization of the released inorganic arsenic by sorption. Characterization techniques, such as FESEM, XRD, FTIR-ATR, DRS and XPS were used to characterize as-prepared membranes so as to analyze their structural and functional attributes. Dynamic cyclic experiments indicated that a satisfactory degradation efficiency of ROX (∼100%) could be achieved by the photocatalytic process within 5 h. Simultaneously, the released inorganic arsenic could be completely converted to As(V) and eventually immobilized onto the surface of membrane. The critical reactive oxidation species (ROS) including O2−, h+ and OH contributed to the photodegradation of ROX, and the PDA coating played multiple roles as an adhesive interface, an electron transfer layer, and an active adsorptive layer. Additionally, based on the HPLC-AFS and GC–MS analysis, the major degradation products were detected and the mechanism of ROX degradation and simultaneous arsenic immobilization by BiOCl0.875Br0.125/PDA functionalized PVDF membranes (BPMs) was given, and the reaction pathway of ROX during the photocatalytic/filtration process was also taken into consideration. Combined with the exceptional photocatalytic property and high adsorption capacity of arsenic, the fabricated BPMs may open new opportunities for the control of ROX in water treatment.
- Published
- 2020
30. Decitabine-based chemotherapy followed by haploidentical lymphocyte infusion improves the effectiveness in elderly patients with acute myeloid leukemia
- Author
-
Jihao Zhou, Yu Jing, Mei-Yun Fang, Yonghui Li, Zi-Long Yao, Li-Ping Dou, Xue-Feng Bai, Lijun Gao, Hai-Yan Zhu, Shimei Lian, Lixin Wang, Quan-Shun Wang, Xiang-Shu Jin, Li-Li Wang, Li Yu, and Yushi Yao
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Lymphocyte ,medicine.medical_treatment ,Decitabine ,haploidentical lymphocyte infusion ,acute myeloid leukemia ,Induction therapy ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Medicine ,Chemotherapy ,Hematology ,business.industry ,Myeloid leukemia ,Cancer ,medicine.disease ,Surgery ,Clinical trial ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Clinical Research Paper ,business ,decitabine ,medicine.drug - Abstract
// Yu Jing 1,* , Xiangshu Jin 1,* , Lixin Wang 1,2,* , Liping Dou 1 , Quanshun Wang 1 , Yushi Yao 1 , Shimei Lian 3 , Jihao Zhou 1 , Haiyan Zhu 1 , Zilong Yao 1 , Lijun Gao 1 , Lili Wang 1 , Yonghui Li 1 , Xuefeng Bai 4 , Meiyun Fang 5 and Li Yu 1 1 Department of Hematology, Chinese PLA General Hospital, Beijing, China 2 Department of Hematology, Navy General Hospital of PLA, Beijing, China 3 Department of Hematology, Dalian Municipal Central Hospital, Affiliated Hospital of Dalian Medical University, Dalian, China 4 Department of Pathology and Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA 5 Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China * These authors have contributed equally to this work Correspondence to: Li Yu, email: // Meiyun Fang, email: // Keywords : decitabine, haploidentical lymphocyte infusion, Induction therapy, acute myeloid leukemia Received : November 01, 2015 Accepted : July 16, 2016 Published : August 10, 2016 Abstract In this study, we first initiated a multicenter, single-arm, phase-II clinical trial using decitabine (DAC) (20mg/m 2 for five days) based chemotherapy, followed by haploidentical lymphocyte infusion (HLI) that was applied as induction therapy for elderly patients with AML. Furthermore, the role of HLI infusion was explored in a mouse model. The clinical trial included 29 elderly patients (median age: 64, range 57-77) with AML. Sixteen cases achieved complete remission (CR) and 9 cases achieved partial remission (PR) after the first treatment cycle. Of the patients with PR, 5 subjects achieved remission after the second induction, which brings the overall CR rate to 72.4%. The 2-year overall survival (OS) and disease-free survival (DFS) was 59.6% and 36.9% respectively. The treatment regimen was well tolerated with only one patient died of severe pneumonia one month after the first treatment. In the mouse experiment, we found that DAC/HLI significantly enhanced the survival of leukemic mice. These results suggested that DAC-based chemotherapy combined with HLI is an alternative first line induction therapy for elderly patients with AML. This trial is registered at ClinicalTrials.gov (NCT01690507).
- Published
- 2016
31. Non-compartment model to compartment model pharmacokinetics transformation meta-analysis - a multivariate nonlinear mixed model.
- Author
-
Zhiping Wang, Seongho Kim, Sara K. Quinney, Jihao Zhou, and Lang Li 0001
- Published
- 2010
- Full Text
- View/download PDF
32. Microcystis aeruginosa-laden water treatment using peroxymonosulfate enhanced Fe(II) coagulation: Performance and the role of in situ formed Fe3O4
- Author
-
Jie Liu, Zhijie Liang, Zhiwei Zhao, Fuyi Cui, Jihao Zhou, and Wei Peng
- Subjects
biology ,Chemistry ,General Chemical Engineering ,02 engineering and technology ,General Chemistry ,010402 general chemistry ,021001 nanoscience & nanotechnology ,biology.organism_classification ,Persulfate ,01 natural sciences ,Algal bloom ,Industrial and Manufacturing Engineering ,0104 chemical sciences ,Settling ,Dissolved organic carbon ,Environmental Chemistry ,Coagulation (water treatment) ,Microcystis aeruginosa ,Water treatment ,Turbidity ,0210 nano-technology ,Nuclear chemistry - Abstract
In order to eliminate the harm of the algal blooms to the safety of the drinking water production, Fe(II)/peroxymonosulfate (PMS) process was applied as simultaneous oxidation coupled with coagulation to enhance the removal of Microcystis aeruginosa (M. aeruginosa). In comparison with Fe(II)/H2O2 and Fe(II)/persulfate process, the higher removal rate of algae cells and faster settling speed were obtained in Fe(II)/PMS treatment. The removal rate of optical density at 680 nm (OD680), turbidity and dissolved organic carbon (DOC) reached up to 92.3%, 91.1% and 58.3% with the sequential addition of 90 μM Fe(II) and 50 μM PMS in 20 min. The moderate oxidation capacity of PMS in weak alkaline environment lead to the low ratios of damaged cells and algal organic matters (AOMs) release. The aggregation of the in situ formed Fe3O4 could significantly promote the generation and settleability of larger flocs. This study demonstrated that Fe(II)/PMS process might be a promising technology towards algae-laden water treatment.
- Published
- 2020
33. Decitabine shows potent anti-myeloma activity by depleting monocytic myeloid-derived suppressor cells in the myeloma microenvironment
- Author
-
Hai-qing Lin, Guoqiang Li, Qi Shen, Lina Hu, Jihao Zhou, and Xinyou Zhang
- Subjects
0301 basic medicine ,Male ,Cancer Research ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,T-Lymphocytes ,Decitabine ,Apoptosis ,Bone Marrow Cells ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,0302 clinical medicine ,In vivo ,Internal medicine ,medicine ,Tumor Cells, Cultured ,Tumor Microenvironment ,Animals ,Multiple myeloma ,Cell Proliferation ,Mice, Inbred BALB C ,Hematology ,Chemistry ,Myeloid-Derived Suppressor Cells ,General Medicine ,medicine.disease ,Coculture Techniques ,Demethylating agent ,030104 developmental biology ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,Myeloid-derived Suppressor Cell ,Bone marrow ,Multiple Myeloma ,medicine.drug - Abstract
Multiple myeloma (MM) remains incurable. The MM microenvironment supports MM cells’ survival and immune escape. Because myeloid-derived suppressor cells (MDSCs) is important in the MM microenvironment, and demethylating agent decitabine (DAC) can deplete MDSCs in vitro and in vivo, we hypothesized that DAC treatment could inhibit MM by depleting MDSCs in the MM microenvironment. In this study, we used the mouse IL6 secreting, myeloma cell line MPC11 as a model. MDSCs were sorted using magnetic beads and cultured. A transwell coculture assay was used to mimic the microenvironment in vitro. And MPC11-bearing mice model was used to observe the efficacy of DAC treatment in vivo. In vitro coculture assay indicated that MPC11 cells showed significantly lower proliferation rate, less IL6 production and more apoptosis when they were cocultured with bone marrow cells without MDSCs (nonMDSCs) or DAC-treated bone marrow cells (DAC BMs) than with MDSCs or PBS-treated bone marrow cells (CTR BM). Supplementation with M-MDSCs rescued the inhibitory effect of DAC BMs, while additional NOHA supplementation further antagonized the rescue effect of M-MDSCs. In MPC11-bearing mice, the combined treatment of DAC with anti-Gr1 antibody showed synergistic effect on inhibiting tumor growth and promoting T cell infiltration in the tumor tissue. M-MDSC reinfusion also antagonized the efficacy of DAC treatment. DAC treatment can inhibit myeloma cell proliferation and induce enhanced autologous T cell immune response by depleting M-MDSCs in the MM microenvironment. We believe that DAC treatment could improve the prognosis of MM in future.
- Published
- 2018
34. HIF-1α inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
- Author
-
Lei Wang, Xinyou Zhang, Yushi Yao, and Jihao Zhou
- Subjects
0301 basic medicine ,Isoantigens ,Regulatory T cell ,medicine.medical_treatment ,Alpha (ethology) ,Graft vs Host Disease ,chemical and pharmacologic phenomena ,Graft vs Leukemia Effect ,Hematopoietic stem cell transplantation ,Echinomycin ,T-Lymphocytes, Regulatory ,General Biochemistry, Genetics and Molecular Biology ,Disease-Free Survival ,Pathogenesis ,Hypoxia-inducible factor 1 alpha ,03 medical and health sciences ,chemistry.chemical_compound ,In vivo ,immune system diseases ,hemic and lymphatic diseases ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Medicine(all) ,Mice, Inbred BALB C ,Acute graft-versus-host disease ,Biochemistry, Genetics and Molecular Biology(all) ,business.industry ,Research ,hemic and immune systems ,General Medicine ,Regulatory T cells ,T-Lymphocytes, Helper-Inducer ,medicine.disease ,Hypoxia-Inducible Factor 1, alpha Subunit ,Mice, Inbred C57BL ,Leukemia ,030104 developmental biology ,medicine.anatomical_structure ,surgical procedures, operative ,chemistry ,Graft-versus-leukemia effect ,Immunology ,Th17 Cells ,Female ,business ,Ex vivo - Abstract
Background Acute graft-versus-host disease (aGVHD) remains a major obstacle against favorable clinical outcomes following allogeneic hematopoietic stem cell transplantation (allo-HSCT). T helper cells including Th17 play key roles in aGVHD pathogenesis. Donor regulatory T cell (Tregs) adoptive therapy reduces aGVHD without weakening graft-versus-leukemia effect (GVL) in both mouse and human, although the purification and ex vivo expansion of Tregs in clinical scenarios remain costly and technically demanding. Hypoxia-inducible factor 1 alpha (HIF-1α) is a key molecule switch that attenuates Treg but promotes Th17 development. However, whether pharmacological inhibition of HIF-1α reduces aGVHD via increasing Treg development and diminishing Th17 responses remains unexplored. Methods By using alloantigen-specific mixed lymphocyte culture and murine models of aGVHD and GVL, we evaluated the impacts of HIF-1α inhibition by echinomycin on the alloantigen-specific CD4 T cell responses ex vivo, as well as on aGVHD and GVL effect following allo-HSCT. Results Ex vivo echinomycin treatment resulted in increased number of Tregs in the culture as well as reduced alloantigen-specific Th17 and Th1 responses. In vivo echinomycin treatment reduced GVHD scores and prolonged survival of mice following allo-HSCT, which is associated with increased number of donor Tregs and reduced number of Th17 and Th1 in lymphoid tissues. In murine model of leukemia, echinomycin treatment preserved GVL effect and prolonged leukemia free survival following allo-HSCT. Conclusions Echinomycin treatment reduces aGVHD and preserves GVL effect via increasing donor Treg development and diminishing alloantigen-specific Th17 and Th1 responses following allo-HSCT, presumably via direct inhibition of HIF-1α that results in preferential Treg differentiation during alloantigen-specific CD4 T cell responses. These findings highlight pharmacological inhibition of HIF-1α as a promising strategy in GVHD prophylaxis. Electronic supplementary material The online version of this article (doi:10.1186/s12967-017-1132-9) contains supplementary material, which is available to authorized users.
- Published
- 2017
35. Circulating myeloid-derived suppressor cells predict disease activity and treatment response in patients with immune thrombocytopenia
- Author
-
Y Zhou, Xinyou Zhang, J Wen, Jihao Zhou, and Sun Xiongfei
- Subjects
0301 basic medicine ,Male ,Physiology ,Disease ,Treatment response ,Lymphocyte Activation ,Biochemistry ,T-Lymphocytes, Regulatory ,Dexamethasone ,Pathogenesis ,immune system diseases ,hemic and lymphatic diseases ,Disease activity ,General Pharmacology, Toxicology and Pharmaceutics ,lcsh:QH301-705.5 ,lcsh:R5-920 ,biology ,General Neuroscience ,Immunoglobulins, Intravenous ,General Medicine ,Regulatory T cells ,Pathophysiology ,Arginase ,medicine.anatomical_structure ,Female ,Antibody ,lcsh:Medicine (General) ,medicine.drug ,Adult ,T cell ,Immunology ,Biophysics ,Ocean Engineering ,03 medical and health sciences ,medicine ,Humans ,Clinical Investigation ,Purpura, Thrombocytopenic, Idiopathic ,business.industry ,Myeloid-Derived Suppressor Cells ,Cell Biology ,Immune thrombocytopenia ,030104 developmental biology ,lcsh:Biology (General) ,Myeloid-derived suppressor cells ,Case-Control Studies ,biology.protein ,Myeloid-derived Suppressor Cell ,business - Abstract
Immune thrombocytopenia (ITP) is a disease characterized by isolated thrombocytopenia. Abnormal effector T cell activation is an important mechanism in the pathogenesis of ITP. Regulatory T cells (Treg) have a strong immunosuppressive function for T cell activation and their importance in the pathophysiology and clinical treatment of ITP has been confirmed. Myeloid-derived suppressor cells (MDSCs) are other immunosuppressive cells, which can also suppress T cell activation by secreting arginase, iNOS and ROS, and are essential for Treg cells’ differentiation and maturation. Therefore, we speculate that MDSCs might also be involved in the immune-dysregulation mechanism of ITP. In this study, we tested MDSCs and Treg cells in peripheral blood samples of twenty-five ITP patients and ten healthy donors. We found that MDSCs and Treg cells decreased simultaneously in active ITP patients. Relapsed ITP patients showed lower MDSCs levels compared with new patients. All patients received immunosuppressive treatment including dexamethasone alone or in combination with intravenous immune globulin. We found that MDSCs’ level after treatment correlated with platelet recovery. Our study is the first that focused on MDSCs’ role in ITP. Based on our results, we concluded that circulating MDSCs could predict disease activity and treatment response in ITP patients. This preliminary conclusion indicates a substantial significance of MDSCs in the pathophysiology and clinical treatment of ITP, which deserves further investigation.
- Published
- 2017
36. MOESM1 of HIF-1Îą inhibitor echinomycin reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
- Author
-
Yao, Yushi, Wang, Lei, Jihao Zhou, and Xinyou Zhang
- Subjects
Data_FILES - Abstract
Additional file 1. Additional figures.
- Published
- 2017
- Full Text
- View/download PDF
37. Demethylating agent decitabine disrupts tumor-induced immune tolerance by depleting myeloid-derived suppressor cells
- Author
-
Jihao Zhou, Lina Hu, Guoqiang Li, Qi Shen, Yushi Yao, and Xinyou Zhang
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_treatment ,T-Lymphocytes ,Decitabine ,Apoptosis ,Lymphocyte Activation ,Immune tolerance ,03 medical and health sciences ,chemistry.chemical_compound ,Mice ,Immune system ,In vivo ,Cell Line, Tumor ,Neoplasms ,medicine ,Immune Tolerance ,Animals ,Humans ,Myeloid-Derived Suppressor Cells ,General Medicine ,Immunotherapy ,Mixed lymphocyte reaction ,Demethylating agent ,030104 developmental biology ,Oncology ,chemistry ,Immunology ,Myeloid-derived Suppressor Cell ,Azacitidine ,medicine.drug - Abstract
The immunoregulatory effect of demethylating agent decitabine (DAC) has been recognized recently. However, little is known about its impact on immune tolerance. In this study, we aimed to determine the impact of DAC on the immune tolerance induced by tumor cells. The effects of DAC on immune cells in vivo were measured by flow cytometry. Myeloid-derived suppressor cells (MDSCs) were sorted using magnetic beads and cultured in vitro. The mixed lymphocyte reaction was used to determine the immunoregulatory effect of DAC in vitro. An adoptive transfusion mouse model was established to evaluate the effect in vivo. We found that DAC treatment significantly depleted MDSCs in vivo by inducing MDSCs apoptosis. When given at a low dose, the immune effector cells were less affected by the treatment, except for MDSCs. The mixed lymphocyte reaction in vitro showed that T-cell responses were enhanced when MDSCs were depleted. Supplementation of MDSCs would attenuate this T-cell activation effect. Using an adoptive transfusion mouse model, we further demonstrated in vivo that DAC treatment could induce autologous anti-tumor immune response by depleting MDSCs. This study is the first to illustrate DAC’s immunoregulatory effect on immune tolerance. The disruption of immune tolerance is due to MDSCs depletion that induces an autologous immune response in vivo. By depleting MDSCs, DAC treatment removes one of the obstacles affecting anti-tumor immune activation and warrants further experimental and clinical studies to explore its potential utility in combination with various anti-tumor immunotherapies in the future.
- Published
- 2016
38. Facile Preparation of b-Fe2O3/BiOCl0.875Br0.125 Composites for Enhanced Visible-light Photocatalytic Degradation of Organics from Water.
- Author
-
Jihao Zhou, Zhiwei Zhao, Ping Xiao, Jie Liu, Zhaoxia Ding, Yuting Han, and Jie Shi
- Subjects
ORGANIC water pollutants ,WATER purification ,PHOTOCATALYTIC oxidation ,RHODAMINE B ,ENERGY shortages ,PSEUDOPOTENTIAL method - Abstract
Visible light-driven photocatalytic oxidation technology has shown great potential for effective removal of organic pollutants from water and mitigation of energy crises at the same time. The highly effective and economic b-Fe
2 O3 /BiOCl0.875 Br0.125 photocatalyst was prepared by a facile hybrid compositing method with b-Fe2 O3 and BiOCl0.87 5Br0.125 to overcome relatively high material cost and limited catalytic efficiency. Characterization techniques, such as XRD, SEM and XPS were used to study the purity and crystallization characteristics of the as-prepared photocatalyst. Furthermore, taking rhodamine b (RhB) as a simulated organic pollutant, the photocatalytic property of b-Fe2 O3 /BiOCl0.875 Br0.125 with different Bi content was further evaluated by static catalytic degradation test under visible-light. The results indicated that the photocatalytic efficiency of the novel composites increases with the improvement of Bi content. Additionally, in comparison to equal mass of pure phase BiOCl0.875 Br0.125 , when the Bi content reached to 30%, a comparable and even better photocatalysis performance was achieved by the as-prepared b-Fe2 O3 /BiOCl0.875 Br0.125 . The hybrid b-Fe2 O3 /BiOCl0.875 Br0.125 has a potential cost advantage in practical water treatment, and provide an attractive method for fabricating efficient visiblelight-driven photocatalysts. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. Statistical considerations in bioequivalence of two area under the concentration–time curves obtained from serial sampling data
- Author
-
D. L. Hawkins, Steven Y. Hua, and Jihao Zhou
- Subjects
Statistics and Probability ,Logarithm ,Sample size determination ,Statistics ,Degrees of freedom (statistics) ,Inference ,Decision rule ,Statistics, Probability and Uncertainty ,Bioequivalence ,Type I and type II errors ,Mathematics ,Statistical hypothesis testing - Abstract
In this paper, we study the bioequivalence (BE) inference problem motivated by pharmacokinetic data that were collected using the serial sampling technique. In serial sampling designs, subjects are independently assigned to one of the two drugs; each subject can be sampled only once, and data are collected at K distinct timepoints from multiple subjects. We consider design and hypothesis testing for the parameter of interest: the area under the concentration–time curve (AUC). Decision rules in demonstrating BE were established using an equivalence test for either the ratio or logarithmic difference of two AUCs. The proposed t-test can deal with cases where two AUCs have unequal variances. To control for the type I error rate, the involved degrees-of-freedom were adjusted using Satterthwaite's approximation. A power formula was derived to allow the determination of necessary sample sizes. Simulation results show that, when the two AUCs have unequal variances, the type I error rate is better controlled by t...
- Published
- 2013
40. A Randomized Double-blind Placebo-controlled Phase 2 Dose-ranging Study of OnabotulinumtoxinA in Men with Benign Prostatic Hyperplasia
- Author
-
Jihao Zhou, Kyu-Sung Lee, Emmanuel Chartier-Kastler, Denise Bugarin, Joachim Grosse, Anand Patel, Blair Egerdie, Michael Marberger, and Cornelia Haag-Molkenteller
- Subjects
Male ,medicine.medical_specialty ,Urology ,Prostatic Hyperplasia ,Injections, Intralesional ,urologic and male genital diseases ,Placebo ,Placebos ,Double-Blind Method ,Lower Urinary Tract Symptoms ,Quality of life ,Prostate ,Lower urinary tract symptoms ,Post-hoc analysis ,Humans ,Medicine ,Botulinum Toxins, Type A ,Adverse effect ,Aged ,Dose-Response Relationship, Drug ,business.industry ,Middle Aged ,Dose-ranging study ,medicine.disease ,Surgery ,Treatment Outcome ,medicine.anatomical_structure ,Neuromuscular Agents ,International Prostate Symptom Score ,business - Abstract
Botulinum toxin treatment has been investigated as a minimally invasive alternative to oral medications in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (LUTS/BPH).To explore the efficacy of onabotulinumtoxinA 100 U, 200 U, and 300 U versus placebo in men with LUTS/BPH in a phase 2 dose-ranging study.A multicenter double-blind randomized, placebo-controlled 72-wk study enrolled men ≥ 50 yr of age with LUTS/BPH, International Prostate Symptom Score (IPSS) ≥ 12, total prostate volume (TPV) 30-100ml, and maximum flow rate (Q(max)) 5-15 ml/s.Single transperineal (n=63) or transrectal (n=311) administration of placebo (n=94) or onabotulinumtoxinA 100 U (n=95), 200 U (n=94), or 300 U (n=97) into the prostate transition zone.The primary efficacy end point was a change from baseline in IPSS at week 12. Secondary end points were Q(max), TPV, and transition zone volume (TZV). Analysis of covariance and the Cochran-Mantel-Haenszel method assessed the efficacy and proportion of IPSS responders. Adverse events (AEs) were assessed.Significant improvements from baseline in IPSS, Q(max), TPV, and TZV were observed for all groups, including placebo, at week 12 (p0.001), with no significant differences between onabotulinumtoxinA and placebo. However, in an exploratory post hoc analysis, a significant reduction in IPSS versus placebo was observed with onabotulinumtoxinA 200 U in prior α-blocker users (n=180) at week 12. AEs were comparable across all groups.Reductions in LUTS/BPH symptoms were seen in all groups, including placebo, with no significant between-group differences owing to a large placebo effect from the injectable therapy. The findings from the post hoc analysis in men previously treated with α-blockers will be further explored in an appropriately designed study.http://www.Clinical Trials.gov; NCT00284518.
- Published
- 2013
41. Ultrasound irritation enhanced heterogeneous activation of peroxymonosulfate with Fe
- Author
-
Jie, Liu, Jihao, Zhou, Zhaoxia, Ding, Zhiwei, Zhao, Xiao, Xu, and Zhendong, Fang
- Abstract
Magnetic Fe
- Published
- 2016
42. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder
- Author
-
Cornelia Haag-Molkenteller, Heinrich Schulte-Baukloh, Prokar Dasgupta, Eric Rovner, Michael J. Kennelly, and Jihao Zhou
- Subjects
medicine.medical_specialty ,Urinary urgency ,Urinary bladder ,business.industry ,Urinary retention ,Urology ,Urinary incontinence ,Placebo ,medicine.disease ,Dose finding ,medicine.anatomical_structure ,Overactive bladder ,Medicine ,In patient ,Neurology (clinical) ,medicine.symptom ,business - Abstract
Aims We assessed the effects of onabotulinumtoxinA (BOTOX®) on clinical and urodynamic variables in patients with idiopathic overactive bladder (OAB) and urinary urgency incontinence (UUI) with or without detrusor overactivity (DO), inadequately managed with anticholinergics. Methods Three hundred thirteen patients with OAB were randomized to double-blind intradetrusor injection with placebo (n = 44) or 1 of 5 onabotulinumtoxinA doses (50–300 U; n = 269). Primary efficacy variable was change from baseline in UUI episodes/week at week 12. Urodynamic assessments at baseline and weeks 12 and 36 included maximum cystometric capacity (MCC) and volume at first involuntary detrusor contraction (IDC). Results 76.0% of patients had baseline DO. Changes from baseline in MCC and volume at first IDC with onabotulinumtoxinA ≥100 U were superior to placebo at week 12, generally decreasing by week 36. Significant dose-dependent increases in MCC were observed for all onabotulinumtoxinA doses at week 12, and for 150, 200, and 300 U at week 36. Data suggested a dose–response relationship. At week 12 on diary, 15.9% of placebo and 29.8–57.1% of onabotulinumtoxinA 50–300 U recipients, respectively, did not demonstrate UUI. OnabotulinumtoxinA doses >150 U were more commonly associated with post-void residual urine volumes >200 ml. Conclusions Improvements in urodynamic parameters and clinical outcomes generally trended together following onabotulinumtoxinA treatment. This therapy improved key urodynamic parameters in patients with idiopathic OAB and UUI, with no differences in outcomes between those with and those without baseline DO. Therefore, successful idiopathic OAB treatment with onabotulinumtoxinA does not appear to be related to pretreatment finding of DO. 30:556–562, 2011. © 2011 Wiley-Liss, Inc.
- Published
- 2011
43. Dose response with onabotulinumtoxinA for post-stroke spasticity: A pooled data analysis
- Author
-
Amanda M. VanDenburgh, Stuart A. Yablon, Susan M. Garabedian-Ruffalo, Susan Abushakra, Mitchell F. Brin, Frederick C. Beddingfield, and Jihao Zhou
- Subjects
medicine.medical_specialty ,Flexor Carpi Ulnaris ,Urology ,Neurological disorder ,Placebo ,Biceps ,Central nervous system disease ,Muscle tone ,medicine ,Humans ,Spasticity ,Botulinum Toxins, Type A ,Clinical Trials as Topic ,Dose-Response Relationship, Drug ,business.industry ,medicine.disease ,Surgery ,Stroke ,Treatment Outcome ,medicine.anatomical_structure ,Neurology ,Muscle Spasticity ,Upper limb ,Neurology (clinical) ,medicine.symptom ,business - Abstract
Clinical trials demonstrate that onabotulinumtoxinA reduces upper limb post-stroke spasticity, with therapeutic response influenced by injected dose. Individual studies provide limited insight regarding muscle group-specific dose-response relationships. Our objective was to characterize dose-response relationships between onabotulinumtoxinA and muscle tone in specific upper limb muscles. Individual patient data from seven multicenter, randomized, double-blind, placebo-controlled trials were pooled. Of 544 post-stroke patients enrolled, 362 received onabotulinumtoxinA and 182 received placebo, injected into the flexor carpi radialis (FCR), flexor carpi ulnaris (FCU), flexor digitorum superficialis (FDS), flexor digitorum profundus (FDP), and/or biceps brachii (BB). Ashworth Scale score change at week 6 (AshworthCBL) was the primary outcome measure for muscle tone. For a broader analysis of response, AshworthCBL/onabotulinumtoxinA dosage relationships were characterized using three techniques: (1) AshworthCBL plotted as a function of onabotulinumtoxinA dose in Units (U) [dose-response curve]; (2) mean AshworthCBL per onabotulinumtoxinA dose depicting the responses seen with specific dose injection clusters/groups for each specific muscle group; and (3) onabotulinumtoxinA dose estimated to produce a mean 1-point decrease in AshworthCBL as an indicator of clinically meaningful benefit of treatment. Increasing onabotulinumtoxinA doses produced greater AshworthCBLs (muscle tone improvements). The maximal week 6 response (E(max)) model indicated a saturating dose-response relationship, with mean E(max) AshworthCBL values of -1.48, -1.48, -0.63, -0.77, and -0.61 in the FCR, FCU, FDS, FDP, and BB, respectively. OnabotulinumtoxinA doses estimated to produce a mean 1-point decrease in AshworthCBL were: 22.5U, 18.4U, 66.3U, 42.5U in the FCR, FCU, FDS, and FDP, respectively, and not determinable in the BB. These analyses demonstrate a saturating effect of greater muscle tone improvements with increasing onabotulinumtoxinA doses in post-stroke spasticity patients. These findings suggest potentially effective onabotulinumtoxinA doses in selected muscle groups in this study population.
- Published
- 2010
44. A new probabilistic rule for drug–dug interaction prediction
- Author
-
Zhiping Wang, Seongho Kim, Aroonrut Lucksiri, Zhaohui Qin, Lang Li, Jihao Zhou, Menggang Yu, Sara K. Quinney, Jenny Y. Chien, and Stephen D. Hall
- Subjects
Male ,Midazolam ,Monte Carlo method ,Sample (statistics) ,Bayesian inference ,Article ,Bayes' theorem ,Meta-Analysis as Topic ,Statistics ,Econometrics ,Humans ,Computer Simulation ,Drug Interactions ,Pharmacokinetics ,Probability ,Mathematics ,Pharmacology ,Models, Statistical ,Sampling (statistics) ,Bayes Theorem ,Rule-based system ,Fasting ,Ketoconazole ,Area Under Curve ,Cytochrome P-450 CYP3A Inhibitors ,Female ,Constant (mathematics) ,Monte Carlo Method ,Algorithms ,Probabilistic rule - Abstract
An innovative probabilistic rule is proposed to predict the clinical significance or clinical insignificance of DDI. This rule is coupled with a hierarchical Bayesian model approach to summarize substrate/inhibitor's PK models from multiple published resources. This approach incorporates between-subject and between-study variances into DDI prediction. Hence, it can predict both population-average and subject-specific AUCR. The clinically significant DDI, weak DDI, and clinically insignificant inhibitions are decided by the probabilities of predicted AUCR falling into three intervals, (-infinity, 1.25), (1.25, 2), and (2, infinity). The main advantage of this probabilistic rule to predict clinical significance of DDI over the deterministic rule is that the probabilistic rule considers the sample variability, and the decision is independent of sampling variation; while deterministic rule based decision will vary from sample to sample. The probabilistic rule proposed in this paper is best suited for the situation when in vivo PK studies and models are available for both the inhibitor and substrate. An early decision on clinically significant or clinically insignificant inhibition can avoid additional DDI studies. Ketoconazole and midazolam are used as an interaction pair to illustrate our idea. AUCR predictions incorporating between-subject variability always have greater variances than population-average AUCR predictions. A clinically insignificant AUCR at population-average level is not necessarily true when considering between-subject variability. Additional simulation studies suggest that predicted AUCRs highly depend on the interaction constant K(i) and dose combinations.
- Published
- 2009
45. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects
- Author
-
Karen J. Klamerus, Carlo L. Bello, John Smeraglia, Lev Verkh, Janessa Mount, Laurie Sherman, and Jihao Zhou
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Indoles ,Adolescent ,Cmax ,Biological Availability ,Bioequivalence ,Pharmacology ,Food-Drug Interactions ,Pharmacokinetics ,Internal medicine ,Sunitinib ,Humans ,Medicine ,Pyrroles ,Pharmacology (medical) ,Active metabolite ,Cross-Over Studies ,business.industry ,Middle Aged ,Protein-Tyrosine Kinases ,Sunitinib malate ,Crossover study ,Bioavailability ,Endocrinology ,Oncology ,Female ,business ,medicine.drug - Abstract
The effect of food on the oral bioavailability of sunitinib malate (SU11248, an oral, multi-targeted tyrosine kinase inhibitor with anti-angiogenic and anti-tumor activities) was assessed in a randomized open-label, two-way crossover study. A 50-mg dose of SU11248 was administered to 16 healthy subjects after a 10-h fast in one period and after a high-fat, high-calorie meal in the other period. The 90% confidence intervals (CIs) for maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) were within the 80-125% bioequivalence range, indicating the absence of a food effect. SU11248 exposure increased slightly in the fed compared with the fasted state (ratios of fed/fasted geometric least square means: Cmax 104%, AUC0-last and AUC0-infinity both 112%). There was a delay in the formation/absorption of the active metabolite SU12662 in the fed state (mean Cmax decreased 23%), but exposure remained unaffected (90% CIs for AUC0-last and AUC0-infinity were within 80-125%). These results indicate that SU11248 can be administered with or without food.
- Published
- 2006
46. Experimental Study on Removing Inorganic Salts from Groundwater Through Nanofiltration Membrane Process Under Low Operating Pressure.
- Author
-
Lei Sun, Jihao Zhou, Zhengjun Mai, and Zhi Zhang
- Subjects
NANOFILTRATION ,GROUNDWATER ,SALINE water conversion ,WATER security - Abstract
The existence of excessive inorganic salts is a great threat to water security for the surrounding residents in the northwest of China where the groundwater is widely used as the main source of drinking water. Aiming at the target water quality, in order to achieve the economic and efficient desalination and provide guidance for choosing membrane components in the practical membrane process, the performance of water production and ion separation characteristics of the two kinds of nanofiltration (NF) membranes (NF270 and NF90) were studied. The influence of operating pressure and inlet flow on water purifying efficiency by the two commercial NF membranes were also evaluated. The results revealed that under the optimized conditions (0.5 MPa, 350 L·h
-1 ), the ion rejection rates by NF270 reached 99.42%, 81.69%, 34.65% for SO4 2- , F- , Cl- , respectively, whereas the rejection rates by NF90 for SO4 2- , F- , Cl- , NO3- were up to 99.76%, 98.16%, 96.31%, 84.66%, respectively. Consequently, NF270 possesses a stronger ion selective separation property which is more suitable for the removal of bivalent ion with a high permeate flux. While the NF90 can remove nitrate effectively in particular. [ABSTRACT FROM AUTHOR]- Published
- 2019
47. Cost-efficient higher-order crossover designs for two-treatment clinical trials
- Author
-
Jihao Zhou and Ying Yuan
- Subjects
Pharmacology ,Statistics and Probability ,Mathematical optimization ,Cost efficiency ,Computer science ,media_common.quotation_subject ,Crossover ,Crossover study ,Clinical trial ,Direct Treatment ,Order (exchange) ,Statistics ,Pharmacology (medical) ,Function (engineering) ,media_common - Abstract
Higher-order crossover designs have drawn considerable attention in clinical trials, because of their ability to test direct treatment effects in the presence of carry-over effects. The important question, when applying higher-order crossover designs in practice, is how to choose a design with both statistical and cost efficiencies from various alternatives. In this paper, we propose a general cost function and compare five statistically optimal or near-optimal designs with this cost function for a two-treatment study under different carry-over models. Based on our study, to achieve both statistical and cost efficiencies, a four-period, four-sequence crossover design is generally recommended under the simple carry-over or no carry-over models, and a three-period, two-sequence crossover design is generally recommended under the steady-state carry-over models. Copyright © 2005 John Wiley & Sons, Ltd.
- Published
- 2005
48. MP38-01 LONG-TERM EFFICACY AND SAFETY OF REPEAT ONABOTULINUMTOXINA TREATMENT IN OVERACTIVE BLADDER SYNDROME AND URINARY INCONTINENCE: THIRD INTERIM ANALYSIS, MEDIAN 2.4 YEAR FOLLOW-UP
- Author
-
Karl-Dietrich Sievert, Peter K. Sand, Sidney B. Radomski, Christopher R. Chapple, Steven Guard, Jihao Zhou, Christopher Nardo, Victor W. Nitti, and David Sussman
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,Medicine ,Urinary incontinence ,medicine.symptom ,business ,Interim analysis ,Overactive bladder syndrome ,Term (time) - Published
- 2014
49. 150. Long-term efficacy and safety of onabotulinumtoxinA treatment in overactive bladder syndrome and urinary incontinence: interim analysis with median 2.4 years’ follow-up
- Author
-
Christopher R. Chapple, Peter K. Sand, Brenda Jenkins, Jihao Zhou, Sidney B. Radomski, David Sussman, Victor W. Nitti, and Karl-Dietrich Sievert
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,medicine ,Urinary incontinence ,medicine.symptom ,Toxicology ,Interim analysis ,business ,Overactive bladder syndrome ,Term (time) - Published
- 2015
50. The cancer‑testis antigen NXF2 is activated by the hypomethylating agent decitabine in acute leukemia cells in vitro and in vivo
- Author
-
Jihao Zhou, Li-Li Wang, Yonghui Li, Jingxin Li, Min-Hang Zhou, Xiaoning Gao, Mengmeng Jiang, Yushi Yao, Lixin Wang, Li Yu, Li Gao, and Xufeng Luo
- Subjects
Adult ,Male ,Cancer Research ,Antimetabolites, Antineoplastic ,Nucleocytoplasmic Transport Proteins ,medicine.medical_treatment ,Blotting, Western ,Decitabine ,Biology ,In Vitro Techniques ,Real-Time Polymerase Chain Reaction ,Biochemistry ,chemistry.chemical_compound ,Genetics ,medicine ,Tumor Cells, Cultured ,Humans ,RNA, Messenger ,Promoter Regions, Genetic ,Molecular Biology ,Aged ,Aged, 80 and over ,Acute leukemia ,Reverse Transcriptase Polymerase Chain Reaction ,Myeloid leukemia ,RNA-Binding Proteins ,Immunotherapy ,DNA Methylation ,Middle Aged ,Demethylating agent ,Leukemia, Myeloid, Acute ,medicine.anatomical_structure ,Oncology ,Hypomethylating agent ,chemistry ,Case-Control Studies ,Myelodysplastic Syndromes ,Cancer research ,Azacitidine ,Molecular Medicine ,Cancer/testis antigens ,CpG Islands ,Female ,Bone marrow ,medicine.drug - Abstract
Cancer‑testis antigens (CTAs) are a group of tumor‑associated antigens restricted to male germ cells under normal physiological conditions. CTAs are expressed in certain types of tumors and thus are a novel target for immunotherapy. Nuclear RNA export factor 2 (NXF2) is a CTA of which the expression pattern, regulation and clinical significance are unclear. In the present study, following treatment with a demethylating agent, decitabine, NXF2 expression was detected in the majority of the NXF2‑negative acute leukemia cell lines, but not in healthy donor samples. This finding was confirmed by western blot analysis. Eight primary acute leukemia bone marrow samples were treated with decitabine in vitro, and results showed that NXF2 expression was significantly upregulated. In another nine acute myeloid leukemia or myelodysplastic syndrome patients, it was noted that the expression of NXF2 was upregulated in all patients following the first cycle of decitabine, which suggested that NXF2 was activated by decitabine treatment in vivo. Furthermore, NXF2 expression in acute leukemia cells was demonstrated to be regulated by CpG island hypermethylation. To the best of our knowledge, this is the first study to demonstrate that NXF2 is activated by demethylation in acute leukemia cells in vitro and in vivo. NXF2 may therefore serve as a novel target for immunotherapy against acute leukemia.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.